ストックスクリーナーアプリを入手
120.05
2.45%
2.87
前日終値:
$117.18
開ける：
$118.82
24時間の取引高:
1.20M
Relative Volume:
1.07
時価総額：
$6.83B
収益：
$3.99B
当期純損益:
$463.16M
株価収益率:
16.91
EPS:
7.1
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
+8.35%
1か月 パフォーマンス:
-5.05%
6か月 パフォーマンス:
+8.69%
1年 パフォーマンス:
+9.85%
1日の値動き範囲:
$118.75
$120.67
1週間の範囲:
$111.20
$120.67
52週間の値動き範囲:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
名前
Jazz Pharmaceuticals Plc
セクター
電話
353-1-634-7800
住所
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
120.05 | 6.83B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | アップグレード | UBS | Neutral → Buy |
| 2025-02-26 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 開始されました | Goldman | Buy |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-11-27 | ダウングレード | UBS | Buy → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Mkt Perform |
| 2023-06-12 | 再開されました | Wells Fargo | Equal Weight |
| 2022-12-09 | アップグレード | Goldman | Neutral → Buy |
| 2022-06-14 | 開始されました | UBS | Buy |
| 2022-04-06 | ダウングレード | Goldman | Buy → Neutral |
| 2021-11-19 | 再開されました | Goldman | Buy |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-10-05 | 開始されました | Citigroup | Buy |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-05-19 | 再開されました | JP Morgan | Overweight |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-11-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-14 | ダウングレード | Goldman | Neutral → Sell |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 開始されました | Jefferies | Buy |
| 2020-03-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Neutral |
| 2019-08-21 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Peer Perform |
| 2018-11-08 | 繰り返されました | B. Riley FBR | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2018-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 繰り返されました | H.C. Wainwright | Neutral |
| 2018-03-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Jazz Pharmaceuticals Plc (JAZZ) 最新ニュース
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference - Eagle-Tribune
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Brings Sleep Disorder and Cancer Treatment Updates to BofA Healthcare Conference - Stock Titan
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings - The Globe and Mail
PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy - insights.citeline.com
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
3 Unconventional Cannabis Stocks to Watch in 2025 - Yahoo Finance
With A 14% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock? - Yahoo Finance
Antisense Oligonucleotides Market Trends, Growth - openPR.com
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead - Yahoo Finance
3 Reasons To Sell JAZZ And 1 Stock To Buy Instead - Barchart.com
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Gains European Advisory Support for Zanidatamab | JAZZ Stock News - GuruFocus
PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs - Seeking Alpha
Jazz Pharmaceuticals Receives Positive EMA Panel Opinion for Zanidatamab to Treat Biliary Tract Cancer - marketscreener.com
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma - Placera.se
Major Cancer Breakthrough: New Phase 3 Data Reveals Significant Survival Benefits in Lung Cancer Treatment - Stock Titan
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 - PR Newswire UK
TD Cowen maintains Jazz stock Buy rating, $100 target By Investing.com - Investing.com UK
Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma
Canada Pension Plan Investment Board Purchases 8,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ St - GuruFocus
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
JAZZ Vs. HRMY: Which Neuroscience Drugmaker Is The Stronger Play? - Barchart.com
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? - Yahoo Finance
Jazz Sues Alvogen Seeking to Block Copy of Defitelio Liver Drug - Bloomberg Law News
JAZZ vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Yahoo Finance
Is Jazz Pharmaceuticals A Top Cannabis Investment For 2025? - Barchart.com
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? - Zacks Investment Research
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire Inc.
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market Set to Witness - openPR.com
Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
BofA maintains Buy on Jazz Pharmaceuticals stock, target at $213 By Investing.com - Investing.com UK
Where Jazz Pharmaceuticals Stands With Analysts - Benzinga
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Nasdaq
Jazz Pharmaceuticals stock hits 52-week low at $99 By Investing.com - Investing.com Canada
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims - MSN
Jazz Pharmaceuticals at Needham Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Settles Antitrust Claims for $145M - GuruFocus
Jazz Pharmaceuticals Plc (JAZZ) 財務データ
収益
当期純利益
現金流量
EPS
Jazz Pharmaceuticals Plc (JAZZ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | Chairman & CEO |
Apr 01 '25 |
Sale |
123.75 |
1,500 |
185,625 |
440,307 |
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):